newsfilter
← Latest News
Business Wire·

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc, Nasdaq: SLN ("Silence"